Download presentation
Presentation is loading. Please wait.
Published byMihály Nagy Modified over 5 years ago
1
Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases Jennifer W. Leiding, MD, Lisa R. Forbes, MD The Journal of Allergy and Clinical Immunology: In Practice Volume 7, Issue 3, Pages (March 2019) DOI: /j.jaip Copyright © 2019 American Academy of Allergy, Asthma & Immunology Terms and Conditions
2
Figure 1 Jakinib inhibition of JAK-STAT signaling: Cytokines bind their respective receptors and activate janus tyrosine kinase (JAK) proteins, which, in turn, phosphorylate STAT transcription factors to homodimerize or heterodimerize to the nucleus where they direct gene transcription.Shown in this figure are selected cytokines and the corresponding JAK-STAT signal activated. Further shown is where specific JAK inhibitors (Jakinibs) inhibit the activated JAK protein. *IL-2 and IL-15 receptor each have 3 chains. †IL-27 signals through the gp130 receptor chain and can activate STAT1, STAT3 and STAT5. EPO, erythropoietin; JAK, janus kinase. The Journal of Allergy and Clinical Immunology: In Practice 2019 7, DOI: ( /j.jaip ) Copyright © 2019 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.